OTCMKTS:EFTR eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis $0.0008 0.00 (0.00%) As of 10/22/2026 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About eFFECTOR Therapeutics Stock (OTCMKTS:EFTR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get eFFECTOR Therapeutics alerts:Sign Up Key Stats Today's Range$0.0008▼$0.000850-Day Range N/A52-Week Range$0.00▼$0.02Volume500 shsAverage Volume479 shsMarket Capitalization$3.76 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that regulate protein production within cancer cells. Its approach, known as translation control, is designed to interfere with the mechanisms cancer cells use to produce proteins needed for growth, survival and resistance to treatment. The company’s investigational pipeline has included zotatifin (eFT226), an inhibitor of the eukaryotic initiation factor 4A (eIF4A), and tomivosertib (eFT508), an inhibitor of mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2). These programs have been studied as potential treatments for solid tumors and other cancers, both as standalone therapies and in combination with existing treatments. Founded in 2012 and headquartered in San Diego, California, eFFECTOR has operated primarily as a research and development company serving the oncology biopharmaceutical market. The company was led by co-founder Steven A. Worland, who has served as president and chief executive officer. Its therapies remain investigational and are subject to clinical development and regulatory review. AI Generated. May Contain Errors. Read More Receive EFTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EFTR Stock News HeadlinesEFTR - eFFECTOR Therapeutics, Inc.September 25, 2026 | seekingalpha.comeFFECTOR Therapeutics (OTC:EFTR) Stock, Insider Trading ActivityOctober 5, 2024 | benzinga.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 23 at 1:00 AM | Altimetry (Ad)3 Publicly Traded Companies Filing for Bankruptcy as July Kicks OffJuly 15, 2024 | investorplace.comeFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from NasdaqJune 24, 2024 | globenewswire.comeFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian CancerMay 20, 2024 | globenewswire.comEFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024May 9, 2024 | investorplace.comeFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comSee More Headlines EFTR Stock Analysis - Frequently Asked Questions How have EFTR shares performed this year? eFFECTOR Therapeutics' stock was trading at $0.0002 at the beginning of 2026. Since then, EFTR shares have increased by 300.0% and is now trading at $0.0008. How were eFFECTOR Therapeutics' earnings last quarter? eFFECTOR Therapeutics, Inc. (OTCMKTS:EFTR) posted its quarterly earnings data on Monday, November, 8th. The company reported $10.50 earnings per share for the quarter, topping the consensus estimate of ($6.50) by $17.00. The business had revenue of $0.43 million for the quarter. When did eFFECTOR Therapeutics' stock split? eFFECTOR Therapeutics's stock reverse split on the morning of Friday, January 12th 2024.The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of eFFECTOR Therapeutics? Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of eFFECTOR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that eFFECTOR Therapeutics investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Snap (SNAP), CrowdStrike (CRWD), Netflix (NFLX), NVIDIA (NVDA) and PayPal (PYPL). Company Calendar Last Earnings11/08/2021Today10/23/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:EFTR Previous SymbolNASDAQ:EFTR CIK1828522 Webeffector.com Phone858-925-8215FaxN/AEmployees10Year Founded2012Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,700,000Free Float4,483,000Market Cap$3.76 thousand OptionableNo Data Beta2.73 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (OTCMKTS:EFTR) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
